Lockheed Martin Investment Management Co. bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 4,000 shares of the biopharmaceutical company’s stock, valued at approximately $324,000.
Several other institutional investors have also bought and sold shares of the business. Hanson & Doremus Investment Management grew its holdings in shares of Gilead Sciences by 806.5% in the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 1,613 shares during the period. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Gilead Sciences in the second quarter worth $147,000. Harel Insurance Investments & Financial Services Ltd. grew its holdings in shares of Gilead Sciences by 29.3% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 480 shares during the period. Rowland & Co. Investment Counsel ADV bought a new stake in shares of Gilead Sciences in the second quarter worth $153,000. Finally, Capstone Investment Advisors Netherlands B.V. bought a new stake in shares of Gilead Sciences in the second quarter worth $172,000. 75.94% of the stock is owned by institutional investors and hedge funds.
Gilead Sciences, Inc. (GILD) opened at $79.02 on Friday. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The company has a market capitalization of $103,221.38, a PE ratio of 9.00, a PEG ratio of -1.68 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. During the same period in the previous year, the business earned $2.75 earnings per share. The business’s revenue was down 13.2% on a year-over-year basis. sell-side analysts predict that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were given a $0.52 dividend. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.63%. Gilead Sciences’s payout ratio is 23.69%.
GILD has been the topic of several analyst reports. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 target price on the stock in a research report on Friday, October 13th. Berenberg Bank set a $96.00 target price on Gilead Sciences and gave the company a “buy” rating in a research report on Thursday, October 19th. BMO Capital Markets lowered their target price on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating on the stock in a research report on Friday, October 27th. Credit Suisse Group reiterated a “buy” rating and set a $82.00 target price on shares of Gilead Sciences in a research report on Thursday, December 7th. Finally, Mizuho lifted their target price on Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $85.03.
In other news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $75.13, for a total value of $5,509,508.29. Following the transaction, the insider now directly owns 3,070,099 shares in the company, valued at $230,656,537.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the completion of the transaction, the executive vice president now owns 77,363 shares in the company, valued at $5,788,299.66. The disclosure for this sale can be found here. Insiders sold 461,666 shares of company stock worth $34,072,567 over the last 90 days. Company insiders own 1.30% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.